HomepageIMMP • NASDAQ
add
Immutep Ltd - ADR
Vorige slotkoers
$Â 2,76
Jaar-range
$Â 1,32 - $Â 3,53
Beurswaarde
372,74Â mln. USD
Gem. volume
154,54K
Koers/winst
-
Dividendrendement
-
In het nieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (AUD) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 3,01Â mln. | 91,46% |
Bedrijfskosten | 2,71Â mln. | 28,25% |
Netto inkomsten | -22,43Â mln. | -100,47% |
Netto winstmarge | -744,36 | -4,70% |
Winst per aandeel | — | — |
EBITDA | -22,45Â mln. | -76,87% |
Effectief belastingtarief | — | — |
Balans
Totale activa
Totale passiva
| (AUD) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 99,13Â mln. | -37,76% |
Totale activa | 147,20Â mln. | -19,27% |
Totale passiva | 48,30Â mln. | 390,07% |
Totaal aandelenvermogen | 98,90 mln. | — |
Uitstaande aandelen | 1,47 mld. | — |
Koers-boekwaardeverhouding | 39,43 | — |
Rendement op activa | -39,08% | — |
Rendement op kapitaal | -57,47% | — |
Kasstroom
Nettomutatie in liquide middelen
| (AUD) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | -22,43Â mln. | -100,47% |
Operationele kasstroom | -14,32Â mln. | -0,36% |
Kasstroom uit beleggingen | 17,66Â mln. | 156,22% |
Kasstroom uit financiering | -56,28K | 73,65% |
Nettomutatie in liquide middelen | 2,67Â mln. | 106,07% |
Vrije kasstroom | -13,87Â mln. | -65,55% |
Over
Immutep Ltd is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.
Prima currently has three main products in its pipeline, all acquired with Immutep:
Eftilagimod alpha, which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer.
IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline.
IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis. Wikipedia
CEO
Opgericht
2001
Website
Werknemers
19
